Turing Pharmaceuticals AG CEO Martin Shkreli shrugged off the angry criticism he has received for sharply hiking the price of the antiparasitic Daraprim (pyrimethamine), saying he had a duty to shareholders to maximize their profit.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?